IL111978A - Dry-compressed paroxetine formulations - Google Patents

Dry-compressed paroxetine formulations

Info

Publication number
IL111978A
IL111978A IL11197894A IL11197894A IL111978A IL 111978 A IL111978 A IL 111978A IL 11197894 A IL11197894 A IL 11197894A IL 11197894 A IL11197894 A IL 11197894A IL 111978 A IL111978 A IL 111978A
Authority
IL
Israel
Prior art keywords
dry
formulations
compressed
compressed paroxetine
paroxetine formulations
Prior art date
Application number
IL11197894A
Other languages
English (en)
Other versions
IL111978A0 (en
Original Assignee
Smithkline Beecham Corporate I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10746644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL111978(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corporate I filed Critical Smithkline Beecham Corporate I
Publication of IL111978A0 publication Critical patent/IL111978A0/xx
Publication of IL111978A publication Critical patent/IL111978A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL11197894A 1993-12-15 1994-12-14 Dry-compressed paroxetine formulations IL111978A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939325644A GB9325644D0 (en) 1993-12-15 1993-12-15 Novel formulation

Publications (2)

Publication Number Publication Date
IL111978A0 IL111978A0 (en) 1995-03-15
IL111978A true IL111978A (en) 2000-07-16

Family

ID=10746644

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11197894A IL111978A (en) 1993-12-15 1994-12-14 Dry-compressed paroxetine formulations

Country Status (35)

Country Link
US (1) US6113944A (de)
EP (1) EP0734260B2 (de)
JP (1) JP3037757B2 (de)
KR (1) KR100367796B1 (de)
CN (1) CN1071116C (de)
AP (1) AP540A (de)
AT (1) ATE180973T1 (de)
AU (1) AU697982B2 (de)
BG (1) BG62755B1 (de)
BR (1) BR9408219A (de)
CA (4) CA2274387A1 (de)
CZ (1) CZ287891B6 (de)
DE (1) DE69419033T2 (de)
DK (1) DK0734260T4 (de)
DZ (1) DZ1835A1 (de)
ES (1) ES2132610T5 (de)
FI (1) FI962445A0 (de)
GB (1) GB9325644D0 (de)
GR (1) GR3031047T3 (de)
HU (1) HUT75880A (de)
IL (1) IL111978A (de)
MA (1) MA23395A1 (de)
MY (1) MY112123A (de)
NO (1) NO307366B1 (de)
NZ (1) NZ277790A (de)
OA (1) OA10297A (de)
PL (1) PL314980A1 (de)
RO (1) RO115413B1 (de)
RU (1) RU2146141C1 (de)
SA (1) SA94150373B1 (de)
SI (1) SI0734260T2 (de)
SK (1) SK282620B6 (de)
UA (1) UA42745C2 (de)
WO (1) WO1995016448A1 (de)
ZA (1) ZA949900B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086053A1 (en) * 1993-12-15 2002-07-04 Smithkline Beecham Plc Formulations, tablets of paroxetine and process to prepare them
AR001982A1 (es) * 1995-02-06 1998-01-07 Smithkline Beecham Plc Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
GB9605828D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Treatment method
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
EE03970B1 (et) 1997-06-10 2003-02-17 Synthon B.V. 4-fenüülpiperidiinühend, selle valmistamine ja kasutamine ning seda sisaldav ravim
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
US6699882B2 (en) 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
US6168805B1 (en) 1998-05-07 2001-01-02 Endo Pharmaceuticals, Inc. Aqueous process for manufacturing paroxetine solid dispersions
GB9810181D0 (en) * 1998-05-13 1998-07-08 Smithkline Beecham Plc Novel formulations
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
WO2000078290A2 (en) * 1999-06-22 2000-12-28 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a salt of paroxetine
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
EP1313474A2 (de) * 2000-08-28 2003-05-28 Synthon B.V. Paroxetin-zusammensetzungen und verfahren zu deren herstellung
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
HRP20031073A2 (en) 2001-07-31 2004-04-30 Lundbeck & Co As H Crystalline composition containing escitalopram
WO2003044012A1 (en) * 2001-10-22 2003-05-30 Synthon B.V. N-formyl derivatives of paroxetine
US7396542B2 (en) * 2001-12-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
CN1997374A (zh) * 2004-06-23 2007-07-11 默克公司 雌激素受体调节剂
US20060063737A1 (en) * 2004-08-18 2006-03-23 Holmdahl Lisa K Liquid paroxetine compositions
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
US20060216345A1 (en) * 2005-03-24 2006-09-28 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition including paroxetine
WO2007058998A2 (en) * 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
CN109771381B (zh) * 2017-11-13 2021-02-19 北京福元医药股份有限公司 一种帕罗西汀药物制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50116401A (de) * 1974-03-04 1975-09-11
ZA813205B (en) * 1980-12-05 1983-03-30 Smith Kline French Lab Dosage units
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
DE3680184D1 (de) * 1985-08-10 1991-08-14 Beecham Group Plc Verfahren zur herstellung von arylpiperidincarbinol.
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
EP0223403B1 (de) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
GB8714707D0 (en) * 1987-06-23 1987-07-29 Beecham Group Plc Chemical process
JPH06502854A (ja) * 1990-11-24 1994-03-31 ビーチャム・グループ・パブリック・リミテッド・カンパニー 老年痴呆、過食症、片頭痛または食欲不振の治療用のパロキセチンの使用
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders

Also Published As

Publication number Publication date
FI962445L (fi) 1996-06-12
SA94150373B1 (ar) 2006-05-27
CZ176396A3 (en) 1996-09-11
CN1071116C (zh) 2001-09-19
ATE180973T1 (de) 1999-06-15
CA2178637C (en) 1997-12-23
DK0734260T4 (da) 2008-09-29
WO1995016448A1 (en) 1995-06-22
MY112123A (en) 2001-04-30
BG62755B1 (bg) 2000-07-31
PL314980A1 (en) 1996-09-30
BR9408219A (pt) 1997-08-26
CZ287891B6 (cs) 2001-03-14
NO307366B1 (no) 2000-03-27
DZ1835A1 (fr) 2002-02-17
DE69419033D1 (de) 1999-07-15
JPH09506602A (ja) 1997-06-30
KR100367796B1 (ko) 2003-07-22
MA23395A1 (fr) 1995-07-01
EP0734260B1 (de) 1999-06-09
NO962547L (no) 1996-06-14
CA2274389A1 (en) 1995-06-22
AU697982B2 (en) 1998-10-22
ES2132610T3 (es) 1999-08-16
CA2214575A1 (en) 1995-06-22
EP0734260B2 (de) 2008-07-09
GB9325644D0 (en) 1994-02-16
NO962547D0 (no) 1996-06-14
CA2214575C (en) 1999-12-07
CN1137236A (zh) 1996-12-04
CA2274389C (en) 2004-09-14
UA42745C2 (uk) 2001-11-15
CA2178637A1 (en) 1995-06-22
NZ277790A (en) 1998-02-26
CA2274387A1 (en) 1995-06-22
BG100648A (bg) 1997-02-28
EP0734260A1 (de) 1996-10-02
FI962445A7 (fi) 1996-06-12
SI0734260T2 (sl) 2008-12-31
ZA949900B (en) 1995-10-10
RO115413B1 (ro) 2000-02-28
FI962445A0 (fi) 1996-06-12
HU9601665D0 (en) 1996-08-28
IL111978A0 (en) 1995-03-15
DK0734260T3 (da) 1999-11-15
HK1012285A1 (en) 1999-07-30
OA10297A (en) 1997-10-07
SK75696A3 (en) 1996-11-06
SI0734260T1 (sl) 1999-08-31
AP540A (en) 1996-09-20
RU2146141C1 (ru) 2000-03-10
JP3037757B2 (ja) 2000-05-08
AP9400704A0 (en) 1995-01-31
SA94150373A (ar) 2005-12-03
DE69419033T2 (de) 1999-11-25
HUT75880A (en) 1997-05-28
US6113944A (en) 2000-09-05
ES2132610T5 (es) 2008-12-16
SK282620B6 (sk) 2002-10-08
GR3031047T3 (en) 1999-12-31
AU1314595A (en) 1995-07-03

Similar Documents

Publication Publication Date Title
AP9400629A0 (en) Vaccine compositions
PL315128A1 (en) Anti-pollutant compositions
IL110665A0 (en) Erection-inducing compositions
EP0721328A4 (de) Camptothecin-formulierungen
ZA945653B (en) Therapeutic compositions
IL111978A0 (en) Dry-compressed paroxetine formulations and their preparation
GB9318641D0 (en) Compositions
ZA946195B (en) Anthelmintic formulations
GB9410252D0 (en) Galenic formulations
GB9323313D0 (en) Clenasing compositions
PL313979A1 (en) Vaccine composition
GB9326425D0 (en) Vaccine compositions
GB9304823D0 (en) Cable-making compositions
GB9306806D0 (en) Disinfectant compositions
GB9323270D0 (en) Disinfectant composition
GB9311030D0 (en) Pharmaceutical formulations
GB9323399D0 (en) Pharmaceutical formulations
GB9409835D0 (en) Compositions
GB9313759D0 (en) Cementiferous compositions
GB9306144D0 (en) Formulations
GB9308622D0 (en) Formulations
GB9324360D0 (en) Therapeutic compositions
GB9304797D0 (en) Pharmaceutical formulations
GB9321676D0 (en) Pharmaceutical formulations
GB9304800D0 (en) Pharmaceutical formulations